FOR COPD

FOR ASTHMA

SYMBICORT 160/4.5 for the maintenance treatment of COPD

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.1,3

In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3

FAST CONTROL

SUSTAINED EFFECT

§Based on IMS data of new prescriptions (June 2016-March 2017).

The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.

SYMBICORT for your asthma patients ≥12 years of age uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

Sustained improvement in lung function was demonstrated in a 12-week efficacy and safety study.1,3

In patients taking SYMBICORT 160/4.5 (n=124) in Study 1, 79% of 2-hour postdose FEV1 improvement occurred at 15 minutes on day of randomization, 89% at week 2, and 90% at end of treatment.1-3

FAST CONTROL

SUSTAINED EFFECT

§Based on IMS data of new prescriptions (June 2016-March 2017).

The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis.

SYMBICORT 160/4.5 for the maintenance treatment of COPD

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3

Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.1,3

The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.

FAST CONTROL

SUSTAINED EFFECT

§Based on IMS data of new prescriptions (June 2016-March 2017).
COPD Efficacy Data

VIEW DATA

View clinical data about the efficacy of SYMBICORT 160/4.5 in COPD.

COPD Safety Profile

LEARN MORE

Learn more about the safety and side effects of SYMBICORT 160/4.5 in COPD.

SYMBICORT $0 Savings Guarantee Program*

READ NOW

Read about how to get the SYMBICORT $0 Savings Guarantee Program.

How to Use Video

WATCH NOW

Watch the video to get more information on how to use the SYMBICORT inhaler.

*Subject to eligibility rules; restrictions apply.

Asthma Efficacy Data

VIEW MORE

View clinical data about the efficacy of SYMBICORT in asthma.

Asthma Safety Profile

LEARN MORE

Learn more about the safety and side effects of SYMBICORT in asthma.

SYMBICORT $0 Savings Guarantee Program*

READ NOW

Read about how to get the SYMBICORT $0 Savings Guarantee Program.

How to Use Video

WATCH NOW

Watch the video to get more information on how to use the SYMBICORT inhaler.

*Subject to eligibility rules; restrictions apply.